Tvardi Therapeutics (TVRD) Inventory Average (2022 - 2025)
Tvardi Therapeutics (TVRD) posted Inventory Average of $1.7 million for Q1 2025, up 9.05% sequentially from $1.5 million in Q4 2024, and down 45.95% YoY from $3.1 million in Q1 2024.
Tvardi Therapeutics (TVRD) Inventory Average (2022 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Inventory Average for 4 years, with the latest figure at $1.7 million in Q1 2025.
- Quarterly Inventory Average fell 45.95% year-over-year to $1.7 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.7 million (down 45.95% YoY) and the FY2024 annual result came in at $2.1 million, down 25.88% from the prior year.
- Inventory Average improved to $1.7 million in Q1 2025 per TVRD's latest filing, from $1.5 million in the prior quarter.
- Over five years, Inventory Average peaked at $3.5 million in Q2 2023 and troughed at $1.5 million in Q4 2024.
- A 4-year average of $2.5 million and a median of $2.6 million in 2022 frame the typical range for Inventory Average.
- The sharpest annual moves came in 2023 and 2024: Inventory Average surged 57.66% in 2023, then tumbled 54.29% in 2024.
- Over 4 years, Inventory Average stood at $2.1 million in 2022, then surged by 57.66% to $3.3 million in 2023, then plunged by 54.29% to $1.5 million in 2024, then climbed by 9.05% to $1.7 million in 2025.
- According to Business Quant data, Inventory Average over the past three periods registered $1.7 million, $1.5 million, and $1.9 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 213.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 707.10 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 90.57 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 137.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 196.36 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.66 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 2.22 Mn |
| Mar 31, 2024 | 3.07 Mn |
| Dec 31, 2023 | 3.33 Mn |
| Sep 30, 2023 | 3.36 Mn |
| Jun 30, 2023 | 3.47 Mn |
| Mar 31, 2023 | 2.95 Mn |
| Dec 31, 2022 | 2.11 Mn |
| Sep 30, 2022 | 2.65 Mn |
| Jun 30, 2022 | 2.68 Mn |
| Mar 31, 2022 | 2.25 Mn |